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Kurt Krapfenbauer1*†, Elisabeth Drucker2 and Dietmar Thurnher1†Abstract
The analysis of biomarkers in saliva as a clinical application offers an attractive, simple and rapid diagnostic tool for
the short- and long-term monitoring of pathological disorders and drug therapy. The collection of saliva, either
in the pure or in its fractionated form, is a relatively easy and non-invasive procedure that is not harmful to the
patients and has no complications at all. However, the fluid collection must be clearly defined due to variations in
saliva composition, flow rate and day-to-day variability. In order to minimise possible variations, saliva from five
patients without squamous cell carcinoma (SCC) pathology and five with suspicion of oral squamous carcinoma
(OSCC) were collected and matched at different days and analysed by two-dimensional polyacrylamide gel
electrophoresis (2DE-PAGE). Approximately 800 spots were identified, corresponding to 151 different gene products.
The list of identified proteins includes a large number of structural proteins like keratins, keratin subunits, enzymes
and enzyme inhibitors, cytokines, immunoglobulins as well as amylase and other salivary specific glycoproteins.
The majority of proteins that are localised in oral epithelia cells were found as unsolved debris in saliva. One of
the identified proteins was significantly overexpressed in OSCC and was selected for further validation by Western
blot analysis.
Keywords: Oral squamous cell carcinoma, Saliva proteomics, Predictive medicine, Targeted prevention, Tailored
therapy, Individual patient profiles, Disease monitoring, Patient self-managementOverview
Head and neck cancers, a group of malignant neoplasias,
are one of the most common forms of cancer worldwide
[1] and most frequently occur as squamous cell carcin-
oma (SCC) of the mouth, pharynx or larynx. Oral squa-
mous cell carcinomas (OSCC) have a poor prognosis
with a 5-year survival rate of 30%–50%, which has not
changed fundamentally over the last decades [2]. This is
partly due to the fact that OSCC usually develops from
asymptomatic lesions and is often diagnosed or treated
only when it reaches an advanced state. The identification
of markers to discriminate tumour from healthy cells* Correspondence: Kurt_krapfenbauer@yahoo.de
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article, unless otherwise stated.already at the earliest stages of malignancy is of critical
importance for clinical diagnosis, as is a reliable differenti-
ation of the tumour stage.
In the past, gene and protein expression profiles from
OSCC tumours have been reported in various studies
using either tumour-derived cell lines [3] or tumour tissue
[4]. Differential expression of genes or proteins in tumour
vs. healthy tissue has revealed abundant biomarker candi-
dates. Some of the genes or proteins have been reported
repeatedly, like metalloproteinases, urokinase or laminins
[5]. Due to differences in methodology and sample size,
these findings are difficult to interpret and no consensus
has been reached as to what markers are suitable to iden-
tify early malignant lesions. Therefore, oncologists still rely
on the classical diagnosis [6]. Furthermore, these studies
analysed tumour markers in tissue biopsies. The ac-
quired information, though important for the staging ofentral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/4.0), which permits unrestricted use,
, provided the original work is properly credited. The Creative Commons Public
mons.org/publicdomain/zero/1.0/) applies to the data made available in this
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pathways involved in carcinogenesis, was only of limited
use for the discovery of screening biomarkers, as brush
biopsy, the only non-invasive method to obtain tumour
tissue, is a time-consuming method requiring highly
trained personnel. Ultimately, diagnosis would be much
improved if reliable tumour markers for OSCC could be
identified in the periphery and sensitive and reliable
routine testing could be performed either in blood or sal-
iva samples. Consequently, circulatory tumour markers
for OSCC have become a focus of research and have been
subject to several studies [7-16]. However, the sensitivity
and specificity of these markers are still rather poor. While
some researchers found a combination of four biomarkers
(CEA, SCC, immune-suppressive acidic protein, Cyfra) to
be rather sensitive (81%) and specific (77.8%) [17] and
even the first three markers alone were still rather sensi-
tive (69%) and even more specific (90.3%) [17,18], others
using a different combination of markers (SCC, CEA,
C19-9, CA125) found a significant correlation only for
SCC [15,16]. However, they pointed out that SCC sensitiv-
ity was rather low (15%–40%), although its specificity was
quite high (70%–90%). Other studies reported even lower
sensitivity and specificity for these markers. Thus, even
a panel of peripheral biomarkers for OSCC does not
provide sufficient sensitivity and specificity to serve as a
diagnostic test yet.
Changes in DNA associated with cancer frequently
translate into alterations in mRNA expression patterns.
Since these changes occur early in cancerogenesis they
might facilitate the detection of malignant events before
they can be detected by other methods. Furthermore,
contrary to proteins, nucleic acids can easily be ampli-
fied and therefore detected more easily. Consequently,
various studies have analysed mRNA expression signature
for their applicability as biomarkers of OSCC in tissue
biopsies either by quantitative RT-PCR or by microarray
experiments [19]. Microarray techniques are powerful
means of generating a lot of analytical data in the frame of
a single experiment. This analytical information is used to
understand the nuance of the genome of a biological sys-
tem and is the basis of comparison of two or more
samples in many cases. Yet the technical difficulty and
high cost of data production, associated with highly time-
consuming data analysis, has contributed to a position
where poor experimental design is common. Many ex-
periments that use microarrays have a low number of
analytical and/or biological replicates, and users of dif-
ferential displays often assume that multiple estimates
of differences generated by a single microarray experi-
ment provide a substitute for experimental replicas. The
reproducibility of the used microarray techniques, as
assayed by regression analysis, co-efficient of variation
or other variance estimation techniques [20], is typicallynot reported. Power analysis, which can be used to infer
the number of samples required to discover a statistically
significant result [20-22], are rarely undertaken. Weak ex-
perimental design, particularly in a field where technical
challenges remain in the production of high-quality data,
can make it difficult or impossible to determine if differ-
ences reported between two or more samples are likely to
reflect variations in a biological system or are solely ana-
lytically derived.
Most studies published so far have analysed OSCC
proteomics or genomics in tissue biopsies. Though the
information gained from such studies is important for
understanding the mechanisms of carcinogenesis and
can lead to the identification of biomarkers or therapeutic
targets, biopsy samples are not suitable for screening
purposes. For early diagnosis and screening of risk popula-
tions, circulatory markers that can predict the develop-
ment of malignancies at an early or even precancerous
stage would be invaluable. Therefore, biomarkers in blood
and, especially in the case of OSCC, saliva are now a focus
of research. Though not all proteins identified in a tumour
will be present in the periphery even those that are might
be at a level below the current detection limits. Therefore,
it is important to integrate the knowledge of tumour and
saliva proteomics. Apart from proteins, blood and other
body fluids contain both DNA and RNA which have
been used as cancer markers and can be used to screen
for new and specific biomarkers. A few studies so far have
analysed the gene expression profile of OSCC in saliva
samples [23].
The genetic aberrations in cancer cells lead to altered
gene expression patterns, which can be identified long
before the resulting cancer phenotypes are manifested.
Changes that arise exclusively or preferentially in cancer,
compared with normal tissue of the same origin, can be
used as molecular biomarkers [24]. Accurately identified,
biomarkers may provide new avenues and constitute
major targets for early detection of cancer and cancer risk
assessment. A variety of nucleic acid-based biomarkers
have been demonstrated as novel and powerful tools for
the detection of cancers [25-27]. However, most of these
markers have been identified either in cancer cell lines or
in biopsy specimens from late invasive and metastatic
cancers. The ability to detect cancer in its earliest stages
using/utilising biomarkers is still limited. Moreover, the
invasive nature of a biopsy makes it unsuitable for cancer
screening in high-risk populations. This suggests a crucial
need for the development of new diagnostic tools that
improve early detection. The identification of molecular
markers in body fluids that predict the development of
cancer already in earliest or precancerous stages would
constitute such a tool. It has been shown that an identical
mutation as present in the primary tumour can be identi-
fied in the body fluids tested from affected patients [28].
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spinal fluid have been used as biomarkers for cancer diag-
nosis [29-31]. More recently, mRNA biomarkers in serum
or plasma have been targets for reverse transcription PCR
(RT-PCR)-based detection strategies in patients with can-
cers [32,33]. Parallel to the increasing number of identified
biomarkers in body fluids is the growing availability of
more powerful and cost-efficient technologies that enable
mass screening for genetic alterations. Recent discovery of
the existence of a large panel of human mRNA in saliva
by microarray technology [23] suggests a novel clinical ap-
proach, so-called salivary transcriptome diagnostics, for
applications in disease diagnostics as well as for normal
health surveillance. It is a high-throughput, robust and re-
producible approach to harness RNA signatures from sal-
iva. Moreover, using saliva as a diagnostic fluid meets the
demands for inexpensive, non-invasive and accessible
diagnostic methodology [34]. In the present study, the
hypothesis that protein expression patterns can be iden-
tified in the saliva of cancer patients and that the differ-
entially expressed transcripts can serve as biomarkers
for cancer detection was tested. The proof-of-principle
disease in this study is OSCC. The rationale is that oral
cancer cells are immersed in the salivary milieu and gen-
etic heterogeneity has been detected in the saliva from pa-
tients with OSCC [35,36].
Methods
Materials
Immobilised pH gradient (IPG) strips and IPG buffers
were purchased from Bio-Rad Laboratories (Hercules,
CA, USA). Acrylamide/piperazine-di-acrylamide (PDA)
solution (37.5:1, w/v) was purchased from Biosolve Ltd.
(Valkenswaard, The Netherlands), and the other reagents
for the polyacrylamide gel preparation were acquired
from Bio-Rad Laboratories. CHAPS was obtained from
Roche Diagnostics (Mannheim, Germany), urea from
AppliChem (Darmstadt, Germany), thiourea from Fluka
(Buchs, Switzerland), 1,4-dithioerythritol (DTE) and EDTA
from Merck (Darmstadt, Germany) and tributylphosphine
(TBP) from Pierce Biotechnology (Rockford, IL, USA). All
reagents were kept at 4°C.
Sample preparation
Saliva from three male and two female patients with
OSCC as well as from ten healthy control persons were
obtained from the General Hospital Vienna (Medical
University of Vienna). The patients were between 42.3
and 64.2 years old. The stage of cancer was defined by
the extent of the lesion and was determined by physical
examination, radiological studies and pathological ana-
lysis and showed the presence of 66% ± 34% tumour cells
in each tumour centre. Tumour species from two OSCC
patients showed a stage of T3 (1 N0, 6 N2) M0, andfrom three patients, a stage of T4 (1 N0, 2 N2) M0. No
tumour cells were detected in the surrounding mucosal
tissue. The study was approved by the ethical committee
of the General Hospital Vienna.
Protocol for saliva collection and storage for using
pre-coated sampling tubes
Sample collection
Human saliva samples were collected from control and
OSCC donors, who spitted into a pre-coated tube after in-
tensive tooth brushing and rinsing the mouth with water.
Tubes were coated with EDTA, serine, cysteine and
metalloproteases as well as with calpains and a mixture of
specific phosphor inhibitors. Due to the optimised com-
position of the pre-coated tubes and based on previous ex-
periments, the mixture showed excellent inhibition effects
and was therefore very well suited for the protection of
saliva proteins directly isolated from the obtained human
samples. It is important to mention that the inhibitor
cocktail contained both irreversible and reversible prote-
ase inhibitors. The protease inhibitors present in the pre-
coated tubes did not form irreversible complexes with the
SH groups of proteins. Consequently, the addition of a
protease inhibitor cocktail to all further stock buffers and
solutions normally protected with protease and phospho-
tase inhibitors - not only during the initial saliva collection
steps - is recommended in the present study. Eppendorf
tubes were first coated with EDTA (0.37 mg/tube ≡
1 mM), and then with aprotinin, Bestatin, calpain inhibitor
I, calpain inhibitor II, chymostatin, E-64, leupeptin, α2-
macroglobulin, Pefabloc SC, pepstain, PMSF, TLCK-HCL
and trypsin inhibitors (each 1 μmol/ml). Additionally to
the normally protease inhibitor cocktail, 1 μmol NaF and
10 μmol NaVO3 were used as specific phosphatase inhibi-
tors in the tubes. The inhibitory power of the tube was
checked with fresh blood samples in combination with
proteases and protease mixtures. In this experiment, a
drastically higher concentration of protease compared to
the concentration usually present in normal blood sam-
ples was used. The inhibitory activity of these tubes was
further tested with a concentrated blood extract and a
concentrated protenase solution. The activity was deter-
mined using the Roche Applied Science Universal Pro-
tease Substrate. Thereby, the proteolytic activities were
typically inhibited by 95% after 1 h at RT and by 90%
after 24 h at 4°C. Similar effects can be assumed for
saliva samples.
One tube proved to be sufficient for the inhibition of
the proteolytic activity of 10 ml saliva. If very high pro-
teolytic activity was present, less than 5 ml saliva/tube
were collected.
After sample collection, the tubes were gently shacked
(not vortexed!!) for approximately 1 min and snap-frozen
in liquid nitrogen.
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chain was maintained until analysis. To separate the super-
natant from the cell debris, the samples (ca. 1.5 mL) were
centrifuged at 3.000 × g for 15 min at 4°C and the cell pel-
lets were washed three times with 20 mM HEPES, pH 7.5,
containing 320 mM sucrose, 1 mM EDTA, 5 mM DTE,
protease inhibitor cocktail (Roche Diagnostics, one tablet
per 50 ml solution), 1 mM PMSF, 0.2 mM Na3VO3 and
1 mM NaF (homogenisation buffer). Suspensions were
transferred in 40 mM Tris, containing 7 M urea, 2 M thio-
urea, 4% CHAPS, 10 mM 1,4-dithioerythriol, 1 mM EDTA,
homogenised using a glass-Teflon potter (20 strokes at
200 rpm, 4°C) and centrifuged at 100,000 × g for 30 min to
sediment not dissolved material [4].
Two-dimensional electrophoresis
Samples were desalted using membrane filter tubes (Merck
Millipore, Amicon Ultra-0.5 mL Centrifugal Filters). The
protein content in the supernatant was determined by the
Coomassie blue method and revealed concentrations be-
tween 8–12 mg/ml. One or two mg of total protein was
applied on immobilised pH 3–10 non-linear gradient
strips, at both the basic and acidic ends. Focusing started
at 200 V after which the voltage was gradually increased to
5,000 V at 3 V/min and continued at 5,000 V for 24 h. The
second dimensional separation was performed in 12%
polyacrylamide gels. After protein fixation with 50% (v/v)
methanol containing 5% (v/v) phosphoric acid for 12 h, the
gels were stained with colloidal Coomassie blue (Novex,
San Diego, CA, USA) for further 24 h. The gels were
destained with H2O and scanned in an Agfa densitometer
(Agfa-Gevaert N.V., Mortsel, Belgium). The images were
processed using Photoshop (Adobe, San Jose, CA, USA)
and PowerPoint (Microsoft, Redmond, WA, USA) soft-
ware. Protein spots were quantified using the Image
Master 2D Elite software (BioRad Laboratories, Hercules,
CA, USA). The percentage of the volume of the spots
representing a certain protein was determined in compari-
son with the total proteins present in the 2-D gel.
Matrix-assisted laser desorption ionisation time-of-flight
mass spectrometry
Protein identification was performed by matrix-assisted
laser desorption ionization time-of-flight mass spectrom-
etry (MALDI-TOF-MS) as previously described [4,5] but
with minor modifications. Briefly, spots were excised,
destained with 30% (v/v) acetonitrile in 0.1 M ammonium
bicarbonate and dried in a Speedvac evaporator (Thermo
Scientific, Waltham, MA, USA). The dried gel pieces were
rehydrated with 5 μl of 5 mM ammonium bicarbonate
(pH 8.8) containing 50 ng trypsin (Promega, Madison, WI,
USA), centrifuged for 1 min and left at room temperature
for about 12 h. After digestion, 5 μl of water were added,
followed by 10 μl of 75% acetonitrile containing 0.3%trifluoroacetic acid 10 min later, centrifuged for 1 min and
the content was vortexed for 2 min. Of the separated li-
quid, 1.5 μl was mixed with 1 μl of saturated alpha-cyano-
4-hydrocinnamic acid in 50% acetonitrile and 0.1% TFA in
water and applied to the sample target. The samples were
analysed in a time-of-flight mass spectrometer (Ultraflex,
Bruker Daltonics) equipped with a reflector and delayed
extraction. An accelerating voltage of 20 kV was used.
Calibration was internal to the samples. Des-Arg-1 brady-
kinin (Sigma-Aldrich, St. Louis, MO, USA) and ACTH
(Sigma) were used as standard peptides. The peptide
masses were matched with the theoretical peptide masses
of all proteins from all species of the SWISS-Prot data-
base. For protein search, monoisotopic masses were used
and a mass tolerance of 0.0025% was allowed. The protein
search was performed using an in-house developed soft-
ware [28]. Proteins not identified in the MS mode were
further characterised by MALDI LIFT-TOF/TOF MS ex-
periments. Thereby, a relatively low voltage of 8 kV was
initially applied for ion acceleration. Fragments generated
from laser-induced dissociation were subsequently raised
to a higher potential (19 kV) in the LIFT cell.
Western blot analysis
Monoclonal antibody (anti-human Gal-7, BioVisions Cat.
Nr. 5647–100) was diluted 1:5,000 in blocking buffer, ap-
plied to the membranes and incubated together for 1 h at
25°C on an orbital shaker. After primary incubation, the
membranes were washed three times for 10 min in
0.05% Tween 20 in PBS and finally one time for 10 min
in PBS only.
After blocking, subsequently, the specifically bound
primary antibody was conjugated with a horseradish
peroxidase-conjugated secondary antibody. For detec-
tion of the bound horseradish peroxidase-conjugated
monoclonal antibody, the membrane was incubated with
SuperSignal WestFemto Maximum Sensitivity Substrate.
The working solution was prepared by mixing equal parts
of the stable peroxide solution and the luminal/enhancer
solution. The 0.125 ml/cm2 working solution of mem-
brane was used. The working solution was stable for 24 h
at room temperature; however, fresh preparation prior to
incubation is strongly recommended.
Results
The fractions enriched in supernatant and cell debris
proteins from saliva samples were analysed by two-
dimensional electrophoresis using broad pH range 3–10
IPG strips. The gels were stained with Coomassie blue,
following the standard protocol already described in
[4,5] because this approach enables identification rates
up to 90%. Furthermore, Coomassie blue is more suit-
able for protein quantification from gels since it shows a
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Figure 2 Two-dimensional map of human saliva proteins.
Supernatant from saliva samples were isolated by centrifugation
and separated on pH 3–10 non-linear IPG strip, followed by 12%
SDS-polyacrylamide gel. The gel was stained with Coomassie blue.
The spots were analysed by MALDI-MS, and the name of identified
proteins are listed in Table 1.
Krapfenbauer et al. The EPMA Journal 2014, 5:20 Page 5 of 15
http://www.epmajournal.com/content/5/1/20Silver stain is more sensitive but exhibits a non-linear
dynamic range and a tendency to stain differently based
on the amino acid composition and post-translational
modifications of a given protein. Up to 800 spots were
detected on each gel (Figures 1 and 2). For the construc-
tion of a two-dimensional protein database for saliva, ap-
proximately 21,000 spots were excised from 2 × 10 2-D
gels and the proteins were identified by MALDI-TOF-
MS. Proteins that could not be identified in the MS
mode were analysed in the TOF/TOF mode. Whereas
the acquisition of a post-source decay (PSD) spectrum
may take considerable time (approximately 20 min) when
stepping down the reflector voltage, the product ions from
laser-induced metastable decay can be recorded in a
MALDI TOF/TOF instrument employing the LIFT tech-
nology. This enables the rapid (seconds) detection of all
fragments without changing the reflector voltage, which,
compared to conventional PSD, is particularly advanta-
geous for the detection of low mass ions of low abun-
dance. The identified proteins were the products of
different genes. Further, the major differences in the pro-
tein level in the supernatant and cell debris fractions from
cancer patients and healthy individuals were studied.
Saliva samples from five control persons and five pa-
tients with suspicion of oral squamous carcinoma were in-
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Figure 1 Two-dimensional map of human saliva proteins.
Epithelial cell proteins from control patients were isolated from
saliva by different sucrose centrifugation steps and separated on
pH 3–10 non-linear IPG strip, followed by 12% SDS-polyacrylamide
gel. The gel was stained with Coomassie blue. The spots were
analysed by MALDI-MS, and the names of identified proteins are
listed in Table 1.corresponding to 151 different gene products. The list of
identified proteins (see Table 1) included a large number
of structural proteins like keratins, keratin subunits, en-
zymes and enzyme inhibitors, cytokines, immunoglobulins
as well as amylase and other salivary specific glycopro-
teins. The majority of the identified proteins had their ori-
gin in oral epithelia cells and were found as unsolved
debris in saliva (see Figures 1 and 2). Twenty-five proteins
seemed to be specific for SCC and were identified in the
saliva of all patients with suspicion of OSCC, but not in
healthy individuals, by two-dimensional polyacrylamide
gel electrophoresis (2DE-PAGE) (see Table 2).
Cofilin, C-reactive protein precursor, creatine kinase
M-chain, fatty acid binding protein, keratin type II, my-
osin light chain 2 and 3, nucleoside diphosphate kinase
A, phosphoglycerate mutase 1, plakoglobulin and retin-
oic acid binding protein II were not previously described
to be differentially expressed in the OSCC proteome of
saliva. Figures 1 and 2 show examples of 2DE-PAGES of
saliva samples from OSCC patients. The identified pro-
teins that were expressed at altered levels have various
functions. They are involved in cellular transport and
chaperoning, like the heat shock protein (27 kDa) and
the heat shock-like protein p20 (20 kDa), in regulatory
functions, like creatine kinase, pyruvate kinase M1 and
nucleoside diphosphate kinease A, or in the glycolic path-
way, like phosphoglycerale mutase and argininosuccinate
Table 1 List 1: identified proteins in human saliva
Loc. Swiss-Prot.-Nr. Mat. pMism. Protein name
B CHR14-ALC2 5 pMism:7.51 Ig alpha-2 chain C region was used to identify this gene
B CHR5-MY10 6 pMism:6.88 Myosin X was used to identify this gene
B CHR20-CAC24982 5 pMism:8.84 tr:cac24982: sequence 26 from patent wo0100806 precursor was used to identify this gene
A CHR1-CAC32430 7 pMism:10.65 tr:cac32430: sequence 17 from patent wo0105971 was used to identify this gene
A CHR12-CAD48670 7 pMism:8.20 tr:cad48670: sequence 1 from patent wo0229058 was used to identify this gene
A CHR11-Q14697 9 pMism:7.93 tr:q14697: glucosidase II precursor (kiaa0088 protein) was used to identify this gene
A CHR12-Q8N1N4 6 pMism:7.53 tr:q8n1n4: hypothetical protein FLJ39100 was used to identify this gene
A CHR1-Q8N613 9 pMism:9.63 tr:q8n613: chromosome 1 open reading frame 10 was used to identify this gene
A CHRX-Q8NG12 9 pMism:12.95 tr:q8ng12: premature ovarian failure 1b protein was used to identify this gene
A CHR14-Q96HE7 8 pMism:12.21 tr:q96he7: ERO1 (S. cerevisiae)-like was used to identify this gene
A SW:143S_HUMAN 5 pMism:11.49 14-3-3 protein sigma (stratifin) (epithelial cell marker protein 1)
A SW:143Z_HUMAN 6 pMism:9.24 14-3-3 protein zeta/delta (protein kinase C inhibitor protein 1)
A SW:GR78_HUMAN 7 pMism:8.88 78 kDa glucose-regulated protein precursor (GRP 78)
A, B SW:ACTS_HUMAN 5 pMism:8.20 Actin, alpha skeletal muscle (alpha-actin 1)
A, B SW:ACTB_HUMAN 9 pMism:14.16 Actin, cytoplasmic 1 (beta-actin)
A SW:ARP3_HUMAN 6 pMism:8.94 Actin-like protein 3 (actin-related protein 3) (actin-2)
A SW:ADK_HUMAN 5 pMism:8.34 Adenosine kinase (EC 2.7.1.20) (ak)
A SW:SAHH_HUMAN 6 pMism:8.76 Adenosylhomocysteinase (EC 3.3.1.1)
A SW:ALDX_HUMAN 4 pMism:7.16 Alcohol dehydrogenase [NADP+] (EC 1.1.1.2)
A SW:CRAB_HUMAN 4 pMism:10.61 Alpha crystallin B chain (alpha(B)-crystallin) (rosenthal fiber component)
A, B SW:ENOA_HUMAN 9 pMism:13.48 Alpha enolase (EC 4.2.1.11) (2-phospho-d-glycerate hydro-lyase)
A, B SW:ENOL_HUMAN 5 pMism:7.02 Alpha enolase, lung specific (EC 4.2.1.11)
B SW:A2HS_BOVIN 6 pMism:9.32 Alpha-2-HS-glycoprotein precursor (Fetuin-a) (asialofetuin)
A SW:AAC4_HUMAN 8 pMism:9.52 Alpha-actinin 4 (non-muscle alpha-actinin 4)
B SW:AMYC_HUMAN 9 pMism:9.61 Alpha-amylase 2b precursor (EC 3.2.1.1)
A, B SW:AMYS_HUMAN 9 pMism:13.68 Alpha-amylase, salivary precursor (EC 3.2.1.1)
A SW:ACTZ_HUMAN 4 pMism:10.27 Alpha-centractin (centractin) (centrosome-associated actin homolog)
A SW:ANX4_HUMAN 9 pMism:14.41 Annexin A4 (annexin IV) (Lipocortin IV) (Endonexin I)
A SW:ANX8_HUMAN 1 pMism:15.43 Annexin A8 (annexin VIII) (vascular anticoagulant-beta)
A SW:ANX1_HUMAN 9 pMism:17.87 Annexin I (lipocortin I) (calpactin II) (chromobindin 9) (p35)
A SW:ANX2_HUMAN 9 pMism:16.80 Annexin II (lipocortin II) (calpactin I heavy chain)
A SW:ANX3_HUMAN 8 pMism:12.81 Annexin III (lipocortin III) (placental anticoagulant protein III)
A SW:ANX6_HUMAN 8 pMism:11.62 Annexin VI (lipocortin VI) (p68) (p70) (protein III) (chromobindin 20)
A, B SW:AOP2_HUMAN 6 pMism:13.04 Antioxidant protein 2 (1-cys peroxiredoxin) (1-cys Prx)
B SW:APA1_HUMAN 6 pMism:9.19 Apolipoprotein a-i precursor (Apo-AI)
A SW:ATPA_HUMAN 4 pMism:7.38 ATP synthase alpha chain, mitochondrial precursor (EC 3.6.3.14)
A SW:ATPB_HUMAN 7 pMism:7.00 ATP synthase beta chain, mitochondrial precursor (EC 3.6.3.14)
B SW:ENOB_HUMAN 6 pMism:8.88 Beta enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase)
A SW:PMGE_HUMAN 6 pMism:14.78 Bisphosphoglycerate mutase (EC 5.4.2.4)
A, B SW:S108_HUMAN 4 pMism:9.18 Calgranulin A (migration inhibitory factor-related protein 8) (MRP 8)
A, B SW:S109_HUMAN 6 pMism:11.89 Calgranulin B (migration inhibitory factor-related protein 14) (MRP 14)
A, B SW:CAH6_HUMAN 8 pMism:17.32 Carbonic anhydrase VI precursor (EC 4.2.1.1) (carbonate dehydratase VI)
A SW:DHCA_HUMAN 6 pMism:10.55 Carbonyl reductase [NADPH] 1 (EC 1.1.1.184) (NADPH-dependent carbonyl reductase 1)
B SW:CATA_HUMAN 10 pMism:14.91 Catalase (EC 1.11.1.6)
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Table 1 List 1: identified proteins in human saliva (Continued)
A SW:CLI1_HUMAN 8 pMism:13.04 Chloride intracellular channel protein 1 (nuclear chloride ion channel 27)
A SW:CLI3_HUMAN 6 pMism:14.75 Chloride intracellular channel protein 3
A SW:COF1_HUMAN 4 pMism:8.17 Cofilin, non-muscle isoform (18 kDa phosphoprotein) (p18)
B SW:CO3_HUMAN 9 pMism:8.91 Complement C3 precursor [contains: C3a anaphylatoxin]
A, B SW:CO1A_HUMAN 7 pMism:13.63 Coronin-like protein p57 (coronin 1A)
A SW:CYTB_HUMAN 4 pMism:8.79 Cystatin B (liver thiol proteinase inhibitor) (CPI-B) (stefin B)
B SW:CYTD_HUMAN 4 pMism:7.88 Cystatin D precursor
A, B SW:CYTS_HUMAN 7 pMism:16.66 Cystatin S precursor (salivary acidic protein-1) (cystatin SA-III)
B SW:CYTT_HUMAN 6 pMism:11.57 Cystatin SA precursor (cystatin S5)
B SW:CYTN_HUMAN 5 pMism:8.38 Cystatin SN precursor (salivary cystatin SA-1) (cystain SA-I)
B SW:CRS3_HUMAN 4 pMism:7.74 Cysteine-rich secretory protein-3 precursor (CRISP-3) (SGP28 protein)
B SW:DSC2_HUMAN 8 pMism:10.10 Desmocollin 2A/2B precursor (desmosomal glycoprotein II and III)
A SW:EML2_HUMAN 6 pMism:8.38 Echinoderm microtubule-associated protein-like 2 (EMAP-2)
A SW:EF11_HUMAN 4 pMism:8.12 Elongation factor 1-alpha 1 (EF-1-alpha-1) (elongation factor 1 a-1)
A SW:EFTS_NEIMA 6 pMism:9.75 Elongation factor ts (EF-Ts)
A SW:ER29_HUMAN 5 pMism:9.47 Endoplasmic reticulum protein ERp29 precursor (ERp31)
A SW:ECHM_HUMAN 6 pMism:9.15 Enoyl-CoA hydratase, mitochondrial precursor (EC 4.2.1.17)
A SW:IF32_HUMAN 6 pMism:11.90 Eukaryotic translation initiation factor 3 subunit 2 (eIF-3 beta)
A, B SW:CAZ1_HUMAN 6 pMism:14.51 F-actin capping protein alpha-1 subunit (capZ alpha-1)
A SW:CAZ2_HUMAN 5 pMism:14.83 F-actin capping protein alpha-2 subunit (capZ alpha-2)
A SW:CAPB_HUMAN 5 pMism:8.35 F-actin capping protein beta subunit (capZ beta)
A SW:FABE_HUMAN 5 pMism:10.80 Fatty acid-binding protein, epidermal (E-FABP)
B SW:FIBB_HUMAN 8 pMism:14.03 Fibrinogen beta chain precursor.
A SW:ALFA_HUMAN 6 pMism:10.30 Fructose-bisphosphate aldolase a (EC 4.1.2.13) (muscle-type aldolase)
A SW:LEG3_HUMAN 5 pMism:9.79 Galectin-3 (galactose-specific lectin 3) (MAC-2 antigen) (IgE-binding protein)
A SW:LEG7_HUMAN 5 pMism:8.58 Galectin-7 (HKL-14) (PI7)
B SW:GELS_HUMAN 4 pMism:7.50 Gelsolin precursor, plasma (actin-depolymerizing factor) (ADF)
A SW:GLNA_HUMAN 4 pMism:8.41 Glutamine synthetase (EC 6.3.1.2) (glutamate-ammonia ligase)
A, B SW:GTP_HUMAN 8 pMism:14.25 Glutathione S-transferase p (EC 2.5.1.18) (GST class-pi)
B SW:GSHB_HUMAN 8 pMism:13.37 Glutathione synthetase (EC 6.3.2.3) (glutathione synthase)
A SW:G3P2_HUMAN 4 pMism:7.38 Glyceraldehyde 3-phosphate dehydrogenase, liver (EC 1.2.1.12)
A SW:GBLP_HUMAN 7 pMism:10.08 Guanine nucleotide-binding protein beta subunit-like protein 12.3 (p205)
A, B SW:HS27_HUMAN 7 pMism:13.08 Heat shock 27 kDa protein (HSP 27) (stress-responsive protein 27)
A, B SW:HS71_HUMAN 8 pMism:13.76 Heat shock 70 kDa protein 1 (HSP70.1) (HSP70-1/HSP70-2)
B SW:HS76_HUMAN 6 pMism:9.56 Heat shock 70 kDa protein 6 (heat shock 70 kDa protein B′)
A, B SW:HS7C_HUMAN 9 pMism:13.07 Heat shock cognate 71 kDa protein
B TR_HUM:AAN65630 6 pMism:6.93 Hepatocellular carcinoma associated protein TB6
A SW:YHU6_YEAST 6 pMism:7.80 Hypothetical 51.1 kDa protein in DCD1-MRPL6 intergenic region
A TR_HUM:Q8N1N4 5 pMism:7.81 Hypothetical protein FLJ39100
B SW:ALC1_HUMAN 6 pMism:13.03 Ig alpha-1 chain C region
B SW:ALC2_HUMAN 6 pMism:9.44 Ig alpha-2 chain C region
B SW:GC1_HUMAN 5 pMism:8.28 Ig gamma-1 chain C region
B SW:KAC_HUMAN 4 pMism:8.20 Ig kappa chain C region
B SW:MUC_HUMAN 7 pMism:10.04 Ig mu chain C region
B SW:MUCB_HUMAN 5 pMism:7.55 Ig mu heavy chain disease protein (bot)
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Table 1 List 1: identified proteins in human saliva (Continued)
B TR_HUM:AAB3083 5 pMism:8.13 Immunoglobulin A heavy chain allotype 2 (fragment)
B SW:IGJ_HUMAN 4 pMism:7.78 Immunoglobulin J chain
A SW:IL1X_HUMAN 4 pMism:8.29 Interleukin-1 receptor antagonist protein precursor (IL-1ra)
A SW:PLAK_HUMAN 4 pMism:8.04 Junction plakoglobin (desmoplakin III)
A SW:K1CM_HUMAN 9 pMism:11.83 Keratin, type I cytoskeletal 13 (cytokeratin 13) (K13) (CK 13)
A SW:K1CN_HUMAN 9 pMism:10.83 Keratin, type I cytoskeletal 14 (cytokeratin 14) (K14) (CK 14)
A SW:K1CO_HUMAN 6 pMism:8.17 Keratin, type I cytoskeletal 15 (cytokeratin 15) (K15) (CK 15)
A SW:K1CP_HUMAN 6 pMism:8.48 Keratin, type I cytoskeletal 16 (cytokeratin 16) (K16) (CK 16)
A SW:K22E_HUMAN 5 pMism:6.69 Keratin, type II cytoskeletal 2 epidermal (cytokeratin 2e)
A SW:K22O_HUMAN 8 pMism:11.65 Keratin, type II cytoskeletal 2 oral (cytokeratin 2p)
A SW:K2C3_HUMAN 7 pMism:8.91 Keratin, type II cytoskeletal 3 (cytokeratin 3) (K3) (CK3)
A, B SW:K2C4_HUMAN 9 pMism:8.81 Keratin, type II cytoskeletal 4 (cytokeratin 4) (K4) (CK4)
A SW:K2C5_HUMAN 8 pMism:8.38 Keratin, type II cytoskeletal 5 (cytokeratin 5) (K5) (CK 5)
A SW:K2CA_HUMAN 9 pMism:9.67 Keratin, type II cytoskeletal 6a (cytokeratin 6a) (CK 6a)
A, B SW:K2CB_HUMAN 9 pMism:9.16 Keratin, type II cytoskeletal 6b (cytokeratin 6b) (CK 6b)
A SW:K2CD_HUMAN 8 pMism:10.74 Keratin, type II cytoskeletal 6d (cytokeratin 6d) (CK 6d)
A, B SW:K2CE_HUMAN 9 pMism:9.76 Keratin, type II cytoskeletal 6e (cytokeratin 6e) (CK 6e)
A SW:K2CF_HUMAN 6 pMism:7.70 Keratin, type II cytoskeletal 6f (cytokeratin 6f) (CK 6f)
A, B SW:TRFL_HUMAN 9 pMism:9.42 Lactotransferrin precursor (lactoferrin)
B SW:ILEU_HUMAN 6 pMism:9.37 Leukocyte elastase inhibitor (LEI) (monocyte/neutrophil elastase inhibitor)
A, B SW:LKHA_HUMAN 9 pMism:14.08 Leukotriene A4 hydrolase (EC 3.3.2.6) (LTA-4 hydrolase)
B SW:PLSL_HUMAN 7 pMism:8.10 L-plastin (lymphocyte cytosolic protein 1) (LCP-1)
A SW:CAPG_HUMAN 4 pMism:7.59 Macrophage capping protein (actin-regulatory protein CAP-G)
A SW:MDHM_HUMAN 7 pMism:8.25 Malate dehydrogenase, mitochondrial precursor (EC 1.1.1.37)
A SW:MASP_HUMAN 9 pMism:12.66 Maspin precursor (protease inhibitor 5)
A SW:PRN3_HUMAN 4 pMism:11.33 Myeloblastin precursor (EC 3.4.21.76) (leukocyte proteinase 3)
B SW:MY10_HUMAN 5 pMism:7.16 Myosin X
A SW:NAGK_HUMAN 7 pMism:12.42 N-acetylglucosamine kinase (EC 2.7.1.59)
B SW:CYPH_HUMAN 4 pMism:7.34 Peptidyl-prolyl cis-trans isomerase a (EC 5.2.1.8) (PPIase)
A SW:PDX1_HUMAN 8 pMism:13.72 Peroxiredoxin 1 (thioredoxin peroxidase 2)
A SW:PDX2_HUMAN 4 pMism:11.27 Peroxiredoxin 2 (EC 1.11.1.) (thioredoxin peroxidase 1)
A SW:PDX5_HUMAN 5 pMism:10.87 Peroxiredoxin 5, mitochondrial precursor (Prx-V)
A, B SW:PMG1_HUMAN 7 pMism:11.60 Phosphoglycerate mutase 1 (EC 5.4.2.1) (EC 5.4.2.4)
B SW:PIGR_HUMAN 9 pMism:14.20 Polymeric-immunoglobulin receptor precursor (poly-Ig receptor)
A SW:PBEF_HUMAN 5 pMism:8.46 Pre-B cell enhancing factor precursor
A, B SW:PRO1_HUMAN 6 pMism:11.37 Profilin I
A, B SW:PIP_HUMAN 6 pMism:15.52 Prolactin-inducible protein precursor (secretory actin-binding protein)
B SW:PDI1_HUMAN 6 pMism:7.53 Protein-arginine deiminase type I (EC 3.5.3.15)
A SW:TGM3_HUMAN 8 pMism:10.61 Protein-glutamine glutamyltransferase E precursor (EC 2.3.2.13)
B SW:PNPH_HUMAN 5 pMism:8.02 Purine nucleoside phosphorylase (EC 2.4.2.1)
A, B SW:PDXK_HUMAN 5 pMism:8.21 Pyridoxine kinase (EC 2.7.1.35)
A SW:KPY1_HUMAN 7 pMism:8.89 Pyruvate kinase, M1 isozyme (EC 2.7.1.40)
B SW:GDIB_HUMAN 8 pMism:9.67 Rab GDP dissociation inhibitor beta (Rab GDI beta)
A SW:IQG1_HUMAN 8 pMism:8.74 Ras GTPase-activating-like protein IQGAP1 (p195)
B TR_HUM:CAC24982 5 pMism:9.62 Sequence 26 from patent wo0100806 precursor
Krapfenbauer et al. The EPMA Journal 2014, 5:20 Page 8 of 15
http://www.epmajournal.com/content/5/1/20
Table 1 List 1: identified proteins in human saliva (Continued)
A, B SW:TRFE_HUMAN 9 pMism:9.41 Serotransferrin precursor (transferrin) (siderophilin)
A, B SW:ALBU_HUMAN 9 pMism:14.83 Serum albumin precursor
A, B SW:SCC1_HUMAN 7 pMism:8.98 Squamous cell carcinoma antigen 1 (SCCA 1)
A SW:GR75_HUMAN 7 pMism:12.04 Stress-70 protein, mitochondrial precursor (75 kDa glucose-regulated protein)
B SW:SYNP_HUMAN 4 pMism:7.15 Synphilin 1 (alpha-synuclein interacting protein)
A SW:TKT_HUMAN 5 pMism:8.13 Transketolase (EC 2.2.1.1) (TK)
A SW:TPIS_HUMAN 7 pMism:11.79 Triosephosphate isomerase (EC 5.3.1.1) (TIM)
A SW:TBA1_HUMAN 8 pMism:16.58 Tubulin alpha-1 chain (alpha-tubulin 1)
A SW:TBA4_HUMAN 7 pMism:12.89 Tubulin alpha-4 chain
A SW:KCY_HUMAN 4 pMism:11.58 UMP-CMP kinase (EC 2.7.4.14) (cytidylate kinase)
A SW:POR1_HUMAN 5 pMism:10.28 Voltage-dependent anion-selective channel protein 1 (VDAC 1)
A SW:POR2_HUMAN 5 pMism:11.75 Voltage-dependent anion-selective channel protein 2 (VDAC 2)
A SW:WDR1_HUMAN 5 pMism:8.27 WD-repeat protein 1 (actin interacting protein 1)
B SW:ZA2G_HUMAN 9 pMism:13.3 Zink-alpha-glycoprotein precursor
A = epithelial cell debris, B = supernatant.
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were also identified (see Table 1). Some of the proteins are
highly tissue specific, like galectin-7, which has been
shown to be restricted to the stratified epithelium and is
involved in the induction of pro-apoptotic functions and
the cell-cell or cell-matrix adhesion.
Results from the OSCC tissue proteome study
In our previous studies [5], OSCC tumour and control tis-
sue from different patients were analysed by proteomic
analysis. Furthermore, the results were compared to the
list of the conducted saliva proteome study. From the
tumour tissues, 350 proteins were identified, of which 16
proteins were upregulated in tumour tissue while 4 were
downregulated in the tumours [5]. Using pathway analysis,
most of the proteins overexpressed in tumours could be
mapped to the p53, c-Myc and N-Myc pathways and
showed a specific induction to the core proteins in OSCC
tumour samples (see Figure 3). While some of the proteins
that were identified as potential biomarkers for OSCC in
our proteomics/pathway study were shown to be associ-
ated to OSCC before, e.g. squamous cell carcinoma anti-
gen 1 (SCCA-1) and 14-3-3sigma (stratifin), others have
not yet been identified. Extending the pathway analysis,
several other biomarker candidates were identified that
could be used for diagnosis of OSCC in saliva samples.
Results from saliva proteome study
Fractions of supernatant and cell proteins were prepared
from saliva samples of each patient as described in the
‘Methods’ section. The whole saliva was used for frac-
tioning taking into consideration that differences in cell
distribution might exist. Additionally, this approach di-
minishes artifacts that could have been introduced duringthe preparation of saliva samples. The enriched super-
natant and cell debris proteins in the corresponding sub-
fractions were assessed by 2-D gels. Thus, α-enolase and
pyruvate kinase were mainly present in the supernatant
fraction, whereas the peroxisomal protein catalase, which
was co-isolated with the cell debris proteins, was present
in the insoluble fraction.
Preliminary results of our study show, e.g. that galectin-
7 can be efficiently detected in the saliva of healthy and
tumour bearing patients and is strongly overrepresented
in tumour saliva samples (see Figure 4). Other OSCC bio-
marker candidates like stratifin, SCCA-1 and kallikrein-7
will be analysed as well.
For the initial validation of biomarkers and antibodies,
quantitative Western blots will be used. After the suitabil-
ity of the biomarker has been confirmed highly sensitive,
ELISA assays or protein arrays will be developed using
only highly specific antibodies.
Discussion
In the present study, the protein levels in saliva from
OSCC and control patients were quantified with the goal
to detect differences in the protein concentrations that
could serve as markers for the disease. Diagnosis of
OSCC can be difficult in certain clinical situations, even
with histological examination of the lesion. Therefore,
the use of saliva or serological markers may allow earlier
tumour detection and timely intervention. To be useful
as a screening or stratification marker, a protein should
be expressed in minimal amounts. A differential expres-
sion of at least 1.5-fold was chosen in the present study
since this difference enables a reproducible detection by
current technologies. The question exists to what per-
centage a protein should be overexpressed in a tumour





Full protein name Acc. Nr.
sw:ENOA_HUMAN 0 33 Alpha enolase (EC 4.2.1.11) (2-phospho-D-glycerate hydro-lyase)
(non-neural enolase) (NNE) (enolase 1) (phosphopyruvate
hydratase)
P06733 Q16704 Q9UM55
sw:K1CQ_HUMAN 0 17 Keratin, type I cytoskeletal 17 (cytokeratin 17) (K17) (CK 17) (39.1) Q04695
sw:G3P2_HUMAN 0 12 Glyceraldehyde 3-phosphate dehydrogenase, liver (EC 1.2.1.12)
(GAPDH)
P04406
sw:FSC1_HUMAN 0 11 Fascin (singed-like protein) (55 kDa actin bundling protein) (p55) Q16658 Q96IC5 Q9BRF1
sw:HBA_HUMAN 0 11 Hemoglobin alpha chain P01922
sw:MASP_HUMAN 0 11 Maspin precursor (protease inhibitor 5) P36952
sw:NDR1_HUMAN 0 11 NDRG1 protein (N-myc downstream-regulated gene 1 protein)
(differentiation-related gene 1 protein) (DRG1) (reducing agents
and tunicamycin-responsive protein) (RTP) (nickel-specific
induction protein CAP43) (RIT42)
Q92597 O15207 Q9NYR6 Q9UK29
sw:PGK1_HUMAN 0 11 Phosphoglycerate kinase 1 (EC 2.7.2.3) (primer recognition protein
2) (PRP 2)
P00558
sw:PLSL_HUMAN 0 10 L-plastin (lymphocyte cytosolic protein 1) (LCP-1) (LC64P) P13796
sw:SCC1_HUMAN 0 10 Squamous cell carcinoma antigen 1 (SCCA-1) (protein T4-A) P29508 Q96J21
sw:TYPH_HUMAN 0 10 Thymidine phosphorylase precursor (EC 2.4.2.4) (TdRPase) (TP)
(platelet-derived endothelial cell growth factor) (PD-ECGF)
(gliostatin)
P19971 Q13390 Q8WVB7
sw:CATA_HUMAN 0 8 Ccatalase (EC 1.11.1.6) P04040
humangp:HCHR12-007545 0 6 tr:q7z793: keratin 6 L was used to identify this gene current
sequence which covers 100.0% of the above current sequence
which is 100.0% identical to the above sequence
HCHR12-007545
sw:TBB5_HUMAN 0 6 Tubulin beta-5 chain P05218 Q8WUC1 Q9CY33
sw:TBBX_HUMAN 0 6 Tubulin beta-5 chain (tubulin 5 beta) P04350
sw:TKT_HUMAN 0 6 Transketolase (EC 2.2.1.1) (TK) P29401
sw:TAL1_HUMAN 0 5 Transaldolase (EC 2.2.1.2) P37837 O00751
sw:VINC_HUMAN 0 5 Vinculin (metavinculin) P18206 Q16450
sw:CAH2_HUMAN 0 4 Carbonic anhydrase II (EC 4.2.1.1) (carbonate dehydratase II) (CA-II)
(carbonic anhydrase C)
P00918 Q96ET9
sw:CERU_HUMAN 0 4 Ceruloplasmin precursor (EC 1.16.3.1) (ferroxidase) P00450 Q14063
sw:GTO1_HUMAN 0 4 Glutathione transferase omega 1 (EC 2.5.1.18) (GSTO 1-1) P78417
sw:ITH4_HUMAN 0 4 Inter-alpha-trypsin inhibitor heavy chain H4 precursor (ITI heavy
chain H4) (inter-alpha-inhibitor heavy chain 4) (inter-alpha-trypsin
inhibitor family heavy chain-related protein) (IHRP) (plasma
kallikrein-sensitive glycoprotein 120) (PK-120) (GP120) (Pro1851)
[contains: GP57]
Q14624 Q15135 Q9P190 Q9UQ54
sw:OTB1_HUMAN 0 4 Ubiquitin thiolesterase protein OTUB1 (EC 3.4.-.-) (otubain 1)
(OTU domain-containing ubiquitin aldehyde-binding protein 1)
(ubiquitin-specific processing protease OTUB1) (deubiquitinating
enzyme OTUB1) (HSPC263)
Q96FW1 Q96II3 Q9NXQ4 Q9P0B8
sw:PLST_HUMAN 0 4 T-plastin P13797
sw:SAHH_HUMAN 0 4 Adenosylhomocysteinase (EC 3.3.1.1) (s-adenosyl-l-homocysteine
hydrolase) (AdoHcyase)
P23526 Q96A36
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differentially expressed proteins identified in saliva have
basal expression levels in healthy patients as well. We
found 25 proteins with altered expression levels in saliva
from OSCC patients (see Table 2), some of which, likephosphoglycerate mutase, glutathione S-transferase, retin-
oic acid binding protein II, cofilin, galectin-7 and C-
reactive protein, have been already described in cancer cell
lines [37,38] but not in the saliva of OSCC patients. Al-






































Figure 3 Schematic result of proteomics study analysed by pathway analysis. The diagram was constructed with the use of the Ingenuity
Pathway Analysis software as described in the ‘Methods’ and ‘Results’ sections. ANXA2, annexin A2; BRCA1, breast cancer 1; CKM, creatinine
kinase M-chain; CRP, c-reactive protein; FN1, fibronectin 1; GSTP1, glutathione S-transferase pi; HSPB1, heat shock protein 27; NME1, nucleoside
diphosphate kinase A; RB1, retinoblastoma; RBL2, retinoblastoma-like protein 2; SFN, 14-3-3sigma, stratifin.
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groups that used the proteomic approach as well [39].
We found that keratin type II is overexpressed not only
in OSCC tissues but also in the saliva, which is in agree-
ment with literature data [40]. Thus, the correspondingFigure 4 Western blot on five saliva samples derived from OSCC and
normalised for WB content, and equal amounts were separated on a SDS-Pgene product was found to be upregulated in different
squamous cell carcinomas and in its hyperproliferative
states. Analysis of 141 epidermoid cancers of head and
neck showed that 96% of tumours were positive for the
keratin type II protein [41]. Its overexpression in OSCChealthy controls was used for validation of galectin-7. B-actin was
AGE gel and detected by galectin-7 specific antibodies.
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constituents of the cytoskeleton as well as implications on
cell shape and cell size (see Figure 5).Squamous cell carcinoma antigen 1
SCCA-1 may act as a protease inhibitor to modulate the
host immune response against tumour cells. It is exclu-
sively expressed in the cytosol of epithelial cancers and
also secreted in plasma by cancerous cells at a low level.
It is thought to be involved in the regulation of prolifera-
tion of carcinoma cells. SCCA-1 may be useful in specific
immunotherapy for cancer patients and may serve as a
paradigmatic tool for the diagnosis and treatment of pa-
tients with OSCC.Creatine kinase M-chain
In OSCC patients, higher levels of creatine kinase M-chain
(CKM) were found too. CKM is a cytoplasmic enzyme and
member of the ATP guanido phosphotransferase protein
family, which reversibly catalyses the transfer of phosphate
between ATP and various phosphogens such as creatine
phosphate. CKM is involved in enzyme homeostasis and
is an important serum marker for myocardial infarction.
It plays an important role in morphology, aggregation
and permeability of cells. The levels of glutathione S-
transferase were increased in the saliva and tumour as
well. Glutathione S-transferases are a family of enzymes
that play important roles in detoxification by catalysing
the conjugation of many hydrophobic and electrophilic
compounds with reduced glutathione. Glutathione S-
transferase pi gene is a polymorphic gene, encoding
functionally different proteins that are thought to be in-
volved in xenobiotic metabolism and play a role in sus-
ceptibility to cancer and other diseases.Integral membrane & 
cytoskeletal
Cell mobility & s
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Figure 5 Important molecular functions and implications on cell shapRetinoic acid-binding protein II
Retinoic acid-binding protein II is a specific carrier protein
belonging to a group of analogues that have a profound ef-
fect on the growth and differentiation of normal, pre-
malignant and malignant epithelial cells in vitro as well as
in vivo. They have the ability to suppress carcinogenesis in
various epithelial tissues, such as oral cavity, skin, lung,
bladder, prostate and mammary glands. Experimental data
in humans have demonstrated that oral administration of
different isoforms of retinoids can prevent pre-cancerous
(squamous metaplastic) oral and bronchial lesions from
progressing to invasive OSCC and can suppress oral
second primary carcinoma in patients with lung SCC or
HNSCC. We found increased levels of retinoic acid-
binding protein in OSCC tissue (Table 1). In vitro studies
showed that retinoic acid-binding protein suppresses the
proliferation of HNSCC cell lines and inhibits the forma-
tion of SCC colonies [42]. The mechanism of retinoic
acid-mediated regulation of human skin growth and dif-
ferentiation remains unknown. It is possible that the
observed effect is the consequence of the fact that retinoic
acid enhances the growth and modulates the differenti-
ation of mucosal epithelial cells. It is also postulated that
the retinoic acid-binding gene is transcriptionally regu-
lated by a newly synthesised regulatory protein which has
the ability to modulate the transcriptional regulatory activ-
ity of a set of nuclear retinoic acid receptors [42].
Nucleoside diphosphate kinase A
NME1, which was overexpressed in OSCC, plays an im-
portant role in cell movement, invasiveness, disease stage
and tumour genesis. Reduced transcript levels of NME1
were previously identified by genome analysis in highly
metastatic cells. The NME1 gene encodes for the A iso-
form of nucleoside disphophate kinase (NDK). Mutationsecretion 
al 
Transcription (10, 6.6%)
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Transport (8, 5.3%)
Signal transduction (14, 9.3%)
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mas. NME1 is regulated by MYC, MYCN and tumour
protein p53.
Galectin-7
Galectin-7 showed increased levels in OSCC tumours as
well as in saliva samples (see Figure 4). Galectin-7 is a
carbohydrate-binding protein, has the ability to bind to
complementary molecules in the extracellular matrix or
on the surface of other cells, is involved in cell-cell and
cell-matrix interactions and is necessary for normal cell
growth control. Expression of galectin-7 is positively al-
tered in certain tumours that exhibit an aggressive pheno-
type. Its expression pattern appears to be associated with
the degree of squamous differentiation, suggesting a po-
tential utilisation of galectin-7 as a biological and differen-
tiation marker in OSCC.
The heat shock proteins, HSP27, HSP60, HSP71, HSP90
As well as the calcium-binding proteins, calreticulin and
calnexin, were also previously detected in other cancer
cells [35]. However, the stress proteins are present in
large amounts in both normal epithelial and tumour
cells, making their potential for use as clinical markers
negligible. It has been shown that heat shock proteins
(HSPs) also participate in essential physiological pro-
cesses, such as regulation of cell cycle, differentiation,
programmed cell death and tumourigenesis. Small heat
shock proteins include HSP60, HSP27, HSP20 and alpha
B-crystallin. HSP20 is transiently expressed during cell
division to differentiate transition, and this phenomenon
prevents differentiating cells from undergoing apoptosis.
HSP20 also protects cells from apoptosis induced by dif-
ferent stimuli or agents, particularly anti-cancer drugs.
Interestingly, tumour cells usually express high levels of
HSP20 and anti-cancer drugs, like cisplatin, which triggers
the accumulation of HSP20. HSP27 and HSP20 are inde-
pendently modulated in response to stress [43]. The over-
expression of HSP27 and the downregulation of HSP20 in
OSCC observed in this study are consistent with the re-
sults from studies of other cancers [44].
The proteins underexpressed in OSCC saliva include
annexin I, heat shock 20 kDa-like protein p20, plakoglobin
and myosin light chains 1, 2 and 3. These proteins were
present in significant levels in normal epithelial tissues,
rendering them clinically irrelevant. Annexin I (ANXA1)
belongs to a family of Ca2+-dependent, phospholipid-
binding proteins that have been implicated in a broad
range of molecular and cellular processes, including
modulation and inhibition of phospholipase A2 and kinase
activity, in signal transduction, the maintenance of cyto-
skeleton and extracellular matrix integrity, tissue growth
and differentiation, inflammation and blood coagulation.
ANXA1 plays a major regulatory role in cell growthregulation and differentiation, neutrophil migration, cen-
tral nervous system response to cytokines, neuroendocrine
secretion and mediation of apoptosis [39]. It is normally
expressed at high levels in a wide range of organs and tis-
sues, is specifically implicated in epithelial differentiation
and growth regulation and is markedly downregulated in
certain other cancers [45], including esophageal squamous
cell carcinomas [46]. Using immunoblots, Bouden and
Krieg [47] found downregulation of annexin I in head and
neck cancer, which agrees with our results. Contrary to
these results, Paweletz et al. [48] used a proteomics ap-
proach and observed increased levels for annexin I in buc-
cal squamous cell carcinoma [48]. Since phospholipase A2
is required for biosynthesis of the potent mediators of
inflammation, prostageomdins and leukotriens, ANXA1
may have potential anti-inflammatory activity.
Carcinogenesis of squamous cells involves alterations
of the adhesive properties of cells to each other as well
as to the basement membrane. In epidermal keratinocytes,
the main cell-cell adhesion systems are adherens junctions
and desmosomes. Plakoglobin is one of the desmosome
components and was reported to be expressed in various
skin carcinomas such as basal cell carcinoma (BCC), SCC,
extra mammary Paget’s disease and Bowen’s disease [49].
In normal human skin, plakoglobin is strongly expressed
in the intercellular space of the epidermis except of the
basal cell layer. We observed that expression of plako-
globin in OSCC was reduced or was absent in tumour
cells. Decreased expression of plakoglobin in skin car-
cinomas is associated with the invasive and metastatic
ability of tumour cells [50].
Expert recommendations
Protein analysis of saliva as a clinical application offers
an attractive, simple and rapid diagnosis tool for the
short- and long-term monitoring of pathological disor-
ders and drug therapy. The collection of saliva, either in
the pure or in the whole form, is a relatively easy and
non-invasive procedure that is not harmful to the pa-
tients and causes no complications at all. The present
study discusses the identification of tumour-related pro-
teins in saliva by proteome analysis, which can be used
for detection and identification of possible marker pro-
teins, specific for OSCC in the head and neck. In the
course of our study, we validated Gal-7 as a potential
screening by Western blot analysis. The results showed a
specificity of around 90% and a sensitivity of 80% (n = 10),
meaning that Gal-7 is a good screening marker for diag-
nosis of OSCC in saliva.
Outlook
Most studies published so far have analysed the OSCC
proteome or genome in tissue biopsies. Though the
information gained from such studies is important for
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can lead to the identification of biomarkers or therapeutic
targets. However, biopsies are not suitable for screening
purposes. For early diagnosis and screening of risk popula-
tions, markers that can predict the development of malig-
nancies at an early stage or even in a precancerous stage
would be invaluable. Therefore, biomarkers in blood and,
especially in the case of OSCC, saliva are now a focus of
research. Screening of saliva as a clinical application offers
an attractive, simple and rapid diagnosis tool for the
short- and long-term monitoring of pathological disorders
and drug therapy. To collect saliva, either in the pure or
in the whole form is a relatively easy and a non-invasive
procedure, and it is not harmful to the patients and has
no complications. Further validation of saliva markers are
still in process and will follow recommendations of the
“EPMA White Paper” [50]. Finally, the authors consider to
create a topic-relevant multidisciplinary projects respond-
ing the needs of the European population (innovative
screening programmes, monitoring of chronic diseases,
patient self-management, etc.) in the course of the scien-
tific calls of “Horizon 2020” [51].
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